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POLICY STATEMENT
HIV Testing and Prophylaxis to
Prevent Mother-to-Child Transmission
in the United States
Committee on Pediatric AIDS
ABSTRACT
Universal HIV testing of pregnant women in the United States is the key to prevention
of mother-to-child transmission of HIV. Repeat testing in the third trimester and rapid
HIV testing at labor and delivery are additional strategies to further reduce the rate of
perinatal HIV transmission. Prevention of mother-to-child transmission of HIV is most
effective when antiretroviral drugs are received by the mother during her pregnancy
and continued through delivery and then administered to the infant after birth.
Antiretroviral drugs are effective in reducing the risk of mother-to-child transmission
of HIV even when prophylaxis is started for the infant soon after birth. New rapid
testingmethods allow identification of HIV-infectedwomen or HIV-exposed infants in
20 to 60 minutes. The American Academy of Pediatrics recommends documented,
routine HIV testing for all pregnant women in the United States after notifying the
patient that testing will be performed, unless the patient declines HIV testing (“opt-
out” consent or “right of refusal”). For women in labor with undocumented HIV-
infection status during the current pregnancy, immediate maternal HIV testing with
opt-out consent, using a rapid HIV antibody test, is recommended. Positive HIV
antibody screening test results should be confirmed with immunofluorescent anti-
body or Western blot assay. For women with a positive rapid HIV antibody test result,
antiretroviral prophylaxis should be administered promptly to the mother and new-
born infant on the basis of the positive result of the rapid antibody test without waiting
for results of confirmatory HIV testing. If the confirmatory test result is negative, then
prophylaxis should be discontinued. For a newborn infant whose mother’s HIV
serostatus is unknown, the health care professional should perform rapid HIV anti-
body testing on the mother or on the newborn infant, with results reported to the
health care professional no later than 12 hours after the infant’s birth. If the rapid HIV
antibody test result is positive, antiretroviral prophylaxis should be instituted as soon
as possible after birth but certainly by 12 hours after delivery, pending completion of confirmatory HIV testing. Themother
should be counseled not to breastfeed the infant. Assistance with immediate initiation of hand and pump expression to
stimulate milk production should be offered to the mother, given the possibility that the confirmatory test result may be
negative. If the confirmatory test result is negative, then prophylaxis should be stopped and breastfeedingmay be initiated.
If the confirmatory test result is positive, infants should receive antiretroviral prophylaxis for 6 weeks after birth, and the
mother should not breastfeed the infant. Pediatrics 2008;122:1127–1134
INTRODUCTION
Continuing technologic and medical advances in the diagnosis, prevention, and treatment of pediatric HIV infection
require ongoing assessment and review of recommendations relating to pediatric HIV infection, including recom-
mendations regarding prenatal and perinatal HIV counseling and testing. Current guidelines are consistent in their
recognition of the importance of universal HIV testing of pregnant women in the United States as the key to
prevention of mother-to-child transmission (MTCT) (also referred to as vertical or perinatal transmission) of HIV. The
American Academy of Pediatrics (AAP) continues to support these guidelines. This policy statement updates the data
that support the guidelines and suggests ways to continue improving the implementation of the recommendations
for universal testing during routine prenatal care.
WHY IS A NEW STATEMENT NEEDED NOW?
There is continued MTCT of HIV in the United States; 397 infants were infected through MTCT in 1999–2001 in areas
conducting enhanced perinatal surveillance.1 These infant infections occurred despite the availability of efficacious
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interventions for preventing such transmission (antiret-
roviral [ARV] prophylaxis to mother and infant, elective
cesarean delivery before the onset of labor and before
rupture of membranes, and complete avoidance of
breastfeeding).2 In recent years, lack of identification of
maternal HIV-infection status has been the primary rea-
son for new infant HIV infections; effective interventions
cannot be implemented unless maternal HIV status is
known. Rapid HIV antibody testing methods now allow
identification of HIV-infected women or HIV-exposed
infants in 20 to 60 minutes3–5 (see also www.cdc.gov/
hiv/topics/testing/rapid/index.htm). Studies have dem-
onstrated the effectiveness of ARV prophylaxis for pre-
venting MTCT of HIV, even when prophylaxis is initiated
after the birth of the infant.6–10 New guidelines from the
Centers for Disease Control and Prevention (CDC)
strengthen the recommendations for routine HIV testing
during pregnancy.11 This report summarizes the recom-
mendations of the AAP regarding HIV testing and pro-
phylaxis to prevent MTCT of HIV, which are consistent
with and supportive of the CDC recommendations.
HIV TESTING
For adults and children 18 months or older, “conven-
tional testing” of blood for the presence of antibodies
against HIV is performed by using a screening enzyme
immunoassay (EIA). If the initial EIA result is positive,
the laboratory repeats the EIA on the same blood sam-
ple, and if the repeat result is positive, the remainder of
the blood is used to perform a confirmatory test, either
immunofluorescent antibody (IFA) or Western blot as-
say. Because children younger than 18 months may
have a positive HIV antibody test result because of the
presence of passively acquired maternal antibody, assays
that directly detect HIV DNA or RNA (generically re-
ferred to as HIV nucleic acid amplification tests) are
required for diagnosis of HIV infection in children
younger than 18 months.12,13 Results of conventional
HIV antibody tests and HIV nucleic acid amplification
tests usually require hours to days to be returned.
“Rapid” HIV antibody tests have been available since
2002.3,5,14 These are screening tests, which means that a
positive test result requires confirmation with an IFA or
Western blot assay. The rapid antibody test is more
sensitive and more specific than the conventional EIA,
so a conventional EIA is not used as the confirmatory
test for a rapid HIV antibody test.15 In 1 study of the
feasibility and benefit of use of the rapid test in pregnant
women already in labor when they presented to health
care professionals, the positive predictive value of the
rapid test was shown to be higher than that of the
conventional EIA.4 That study of 4849 women (HIV
prevalence: 7 in 1000) demonstrated that for the con-
ventional EIA, the sensitivity was 100%, specificity was
99.8%, and the positive predictive value was 76%,
whereas for the rapid HIV test, the sensitivity was 100%,
specificity was 99.9%, and the positive predictive value
was 90%.4
Although it is usually recommended that all HIV an-
tibody screening tests be confirmed before HIV-specific
treatments are started, this can take several weeks, be-
cause there is often a delay between availability of the
results of the screening test and results of the confirma-
tory IFA or Western blot assay. This is not problematic
for a woman identified early in pregnancy, because ini-
tiation of ARV prophylaxis against MTCT generally is not
started until the second trimester. However, it is a prob-
lem for a woman who is late in pregnancy or in labor or
is being tested immediately postpartum. In such in-
stances, time is of the essence in initiating ARV prophy-
laxis to prevent MTCT. Therefore, when women have
positive results of rapid antibody screening late in preg-
nancy, during labor, or within the first few hours of
delivery of the infant, ARV prophylaxis to prevent MTCT
should be instituted promptly on the basis of the positive
results of the screening test. A maternal blood sample for
a confirmatory HIV antibody assay should be obtained
and sent for testing.4,16,17 Prophylaxis should be stopped if
the confirmatory test result is negative.
BENEFITS OF HIV TESTING
HIV testing during pregnancy allows identification of
HIV infection in women who might not know they are
infected. This is important for the health of the woman,
because knowledge of her HIV-infection status will allow
appropriate evaluation, including CD4 T-lymphocyte
count and HIV viral load quantification, initiation of
comprehensive care, and appropriate ARV treatment.
HIV antibody testing early in pregnancy has the added
benefit of allowing the most effective interventions to
prevent MTCT of HIV to be initiated, including ARV
prophylaxis, planning an appropriate mode of delivery
(elective cesarean delivery or vaginal delivery, depend-
ing on maternal viral load near delivery), and avoidance
of breastfeeding. HIV antibody testing later in preg-
nancy, or even after delivery of the newborn infant, still
allows initiation of effective ARV interventions that can
reduce the risk of MTCT of HIV.
Benefits of HIV Testing Early in Pregnancy
Single-Drug ARV Prophylaxis and MTCT of HIV
The 3-part 1994 Pediatric AIDS Clinical Trials Group
study 076 (PACTG 076) regimen is the starting point for
understanding ARV prophylaxis and the prevention of
MTCT of HIV. Among nonbreastfeeding pregnant
women with HIV infection and a CD4 T-lymphocyte
count of greater than 200 cells per mm3, oral zidovudine
(ZDV) prophylaxis initiated after the first trimester, fol-
lowed by administration of intravenous ZDV beginning
at the onset of labor and continued until the cord is
clamped, combined with 6 weeks of oral ZDV adminis-
tered to the infant (2 mg/kg per dose every 6 hours),
reduces the rate of MTCT of HIV from 25% to 8%.18
Among nonbreastfeeding pregnant women with HIV in-
fection, initiation of ZDV prophylaxis before the 28th
week of pregnancy is associated with a lower risk of in
utero transmission of HIV than is prophylaxis initiated at
35 weeks of pregnancy.19
Combination ARV Regimens and MTCT of HIV
Regimens that include combinations of 3 ARV drugs are
more effective for prevention of MTCT of HIV than is
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ZDV alone.20,21 For nonbreastfeeding pregnant women
with HIV infection, successful combination therapy with
3 ARV drugs and resultant reduction of maternal plasma
virus load to below the limits of detection on sensitive
assays (the goal of standard ARV therapy) is associated
with rates of MTCT of HIV of less than 1%.22–24 Current
US Public Health Service (USPHS) guidelines for preven-
tion of MTCT of HIV recommend use of combination
ARV regimens including at least 3 ARV drugs during
pregnancy and labor for all pregnant women with HIV
infection. ARV drugs are discontinued after delivery un-
less the mother requires ARV therapy for her own
health, in which case ARV therapy would be contin-
ued following guidelines for nonpregnant HIV-in-
fected adults.25,26 Intravenous ZDV should be adminis-
tered to the pregnant woman during labor until the cord
is clamped, with the other ARV drugs in the regimen
continued orally during labor, and all infants should
receive 6 weeks of ZDV prophylaxis.25
The full 6-week course of infant ARV prophylaxis,
and careful instructions for its administration, should be
provided to the family before discharge from the hospi-
tal. A prescription and recommendations to purchase
ZDV for use by the infant are not adequate to ensure
appropriate prophylaxis. In some states, infants may not
be registered for insurance for a few weeks after birth, so
even if the family has insurance, coverage may not be
immediately available to pay for health care costs for the
infant. Some families have health insurance that covers
inpatient costs but not prescription medications. Outpa-
tient pharmacies may not stock the infant-dosage form
of ZDV. At hospital discharge, the family should be sup-
plied with the medication itself, along with careful in-
structions for its administration, not just a prescription.
Mode of Delivery and MTCT of HIV
Elective cesarean delivery (performed before onset of
labor and before rupture of membranes) can prevent
MTCT of HIV27 and is associated with at least a 50%
decrease in the risk of MTCT among HIV-infected
women either not receiving ARV drugs or receiving ZDV
alone.28 Although several studies have suggested that
elective cesarean delivery performed before labor onset
and before rupture of membranes may remain effective
among HIV-infected women with low virus load (low
either intrinsically off ARV therapy or low because of
administration of combination ARV regimens during
pregnancy), further research is required to definitively
demonstrate whether elective cesarean delivery can fur-
ther reduce the risk of MTCT of HIV for women being
successfully treated with combinations of 3 or more ARV
drugs (eg, virus load undetectable on sensitive assays
while on a combination 3-drug ARV regimen).29 Current
American College of Obstetricians and Gynecologists
(ACOG)30 and USPHS guidelines for prevention of MTCT
recommend elective cesarean delivery at 38 weeks’ ges-
tation for all HIV-infected pregnant women with HIV
RNA levels greater than 1000 copies per mL near the
time of delivery (or who have unknown viral load),
regardless of the type of maternal ARV prophylaxis being
received.14,25
Breastfeeding
Breastfeeding confers approximately 9% to 15% excess
risk of MTCT of HIV. In the United States, because safe
infant feeding alternatives exist, women with HIV infec-
tion should not breastfeed regardless of maternal ARV
use.31,32
Benefits of HIV Testing in the Peripartum and Newborn
Periods
When HIV antibody testing is performed before or dur-
ing pregnancy, if a woman is found to be infected with
HIV, it is possible to use all 3 known efficacious inter-
ventions for prevention of MTCT of HIV (prepartum and
intrapartum maternal and postpartum infant ARV pro-
phylaxis, elective cesarean delivery, and avoidance of
breastfeeding). However, if HIV diagnostic testing is not
performed until the peripartum or postpartum periods,
then only 2 of the 3 interventions can be implemented
(intrapartum maternal and postpartum infant ARV pro-
phylaxis and avoidance of breastfeeding). Although ARV
prophylaxis initiated during pregnancy is most effective
at reducing MTCT of HIV, prophylaxis initiated for the
pregnant woman at the time of labor and continued to
the infant after birth, or even prophylaxis only admin-
istered to the infant after birth, can reduce the risk of
MTCT of HIV compared with no prophylaxis.6,7,10 More-
over, identification of HIV exposure allows the pediatri-
cian to offer advice on appropriate alternatives to breast-
feeding, follow-up testing, and prophylaxis against
opportunistic infections for the infant as well as referral
of the mother for care of her HIV infection.12
For the woman with HIV infection identified at the
time of labor, maternal prophylaxis with intravenous
ZDV, together with infant prophylaxis with 6 weeks of
ZDV, is associated with an approximately 60% lower risk
of MTCT of HIV7 compared with no prophylaxis. For
infants whose mothers received no ARV therapy during
pregnancy or labor, prompt (optimally as soon as possi-
ble after birth but certainly within 12 hours after birth)
prophylaxis of the infant with ZDV alone for 6 weeks is
associated with a 50% reduction in the risk of MTCT of
HIV compared with no prophylaxis.7
In certain situations, some experts combine the
6-week infant ZDV prophylaxis regimen with additional
ARV drugs. Such situations might include infants born to
mothers who received prenatal ARV drugs but had sub-
optimal viral suppression at delivery, particularly if the
infant was delivered vaginally; infants born to mothers
who have received only intrapartum ARV drugs; infants
born to mothers who have received no prepartum or
intrapartum ARV drugs; and infants born to mothers
with known drug-resistant virus. Whether combining
ZDV with other ARV drugs provides additional efficacy
for prevention of MTCT of HIV has not been proven in
clinical trials. In addition, appropriate ARV drug formu-
lations and dosing regimens for neonates are incom-
pletely defined for many drugs, and there are minimal
data about the safety of combination ARV drugs in the
neonate. Therefore, use of combination infant ARV pro-
phylaxis involves complex balancing of potential bene-
fits in terms of prevention of MTCT of HIV and risks in
PEDIATRICS Volume 122, Number 5, November 2008 1129
 by guest on June 4, 2019www.aappublications.org/newsDownloaded from 
terms of toxicity to the infant. The USPHS guidelines for
prevention of MTCT of HIV include extensive discussion
of considerations for infant ARV prophylaxis regimens
for different clinical scenarios and should be reviewed
for specific recommendations.25 If infant prophylaxis
with ARV drugs in addition to ZDV is being considered,
decisions and choice of ARV drugs should be determined
in consultation with a practitioner who is experienced in
care of infants with HIV infection.
Other Considerations
Early identification of HIV-exposed infants allows (1)
appropriate testing to identify HIV-infection status of the
infant, (2) counseling of the mother regarding the risk of
HIV transmission through breastfeeding and institution
of appropriate infant feeding, and (3) prophylaxis with
trimethoprim-sulfamethoxazole to prevent Pneumocystis
jiroveci infection for infants whose HIV-infection status
has not been determined or are identified as being HIV
infected.12
SUMMARY: PROPHYLAXIS AND TREATMENT OF PREGNANT
WOMENWITH HIV INFECTION AND THEIR INFANTS
Guidelines for initiation of ARV therapy for pregnant
women are the same as for nonpregnant HIV-infected
adults and follow the USPHS “Guidelines for the Use of
Antiretroviral Agents in HIV-1-Infected Adults and Ad-
olescents”26 except that the choice of ARV drugs includes
special considerations related to pregnancy and fetal
drug exposure as described in the “Recommendations
for Use of Antiretroviral Drugs in Pregnant HIV-Infected
Women for Maternal Health and Interventions to Re-
duce Perinatal HIV Transmission in the United States.”25
For women who need immediate initiation of ARV ther-
apy for their own health, treatment should be initiated
as soon as possible, including in the first trimester. For
women who do not require treatment for their own
health, the effectiveness of ARV prophylaxis depends on
the timing of institution of such prophylaxis. For women
identified as being HIV infected early in pregnancy, gen-
erally 3 ARV drugs are recommended for prophylaxis
during their pregnancy and should be continued until
the time of delivery. Delaying initiation of prophylaxis
until after the first trimester can be considered if treat-
ment of HIV infection is not needed for the woman’s
own health, intravenous ZDV is administered to the
pregnant woman at the time of labor and continued
until the cord is clamped, and the other ARV compo-
nents of the regimen are continued orally during labor.
Oral ZDV is administered to the infant for the first 6
weeks of life.25 For women identified as being HIV in-
fected during labor, intravenous ZDV is recommended
together with infant ARV prophylaxis. For infants born
to women who have not received prepartum or intra-
partum ARV therapy, prophylaxis of the infant with 6
weeks of ZDV is recommended. In the latter 2 situations,
some experts may administer additional ARV drugs to
the mother and/or infant. The USPHS guidelines for
prevention of MTCT of HIV should be consulted for
detailed discussion of these more complex situations,
and decisions for maternal and infant prophylaxis and
therapy in such situations should be made in consulta-
tion with a practitioner who is experienced in care of
infants with HIV infection.25
RISKS OF HIV TESTING IN THE PRENATAL AND NEWBORN
PERIODS
A positive HIV antibody test result for an infant identifies
HIV infection in the mother and HIV exposure (with
possible infection) of the infant. Therefore, even if test-
ing is only performed on the infant after birth, if the
infant is found to be HIV-seropositive, the infant’s
mother will be identified as having HIV infection, which
can be associated with personal psychological trauma
and societal stigma if the mother does not know that she
is infected. Linkage of the newly identified HIV-infected
mother to appropriate psychosocial supports and to HIV
care programs is important. If the test result is found to
be a false-positive, this psychological harm will have
occurred needlessly. Thus, the fact that confirmatory
testing is required to definitively diagnose HIV infection
of the mother, and the need for rapid presumptive treat-
ment of the infant to prevent MTCT should she be HIV
infected, should be explained to the mother when per-
forming rapid testing during labor or after delivery. ARV
administration to the mother and/or infant may be as-
sociated with infant drug toxicity,33–35 and if the rapid
test result is not confirmed to be positive, the benefit/risk
ratio may not favor prophylaxis. However, the infant
should have received only 1 to 2 days of ARV prophy-
laxis in such a situation, and short-term toxicity of ARV
drugs is limited. Expedited confirmatory testing should
be performed to ensure that results are reported quickly
so that the duration of infant exposure to ARV drugs is
minimized.
CONSENT FOR HIV TESTING
Opt-out consent (documented patient notification, with
testing to take place unless rejected by the patient) is
associated with higher testing percentages than opt-in
consent,36–38 and universal HIV screening of pregnant
women with opt-out consent is recommended by the
CDC,11 the ACOG,14 and the AAP.39 As part of its recom-
mendation, the CDC states that HIV screening should be
included in the routine panel of prenatal screening tests
for all pregnant women and that separate written con-
sent for HIV testing should not be required. The CDC
also states that general consent for medical care should
be considered sufficient to encompass consent for HIV
care.11 In states where laws or regulations require writ-
ten informed maternal consent for testing (“opt-in” con-
sent), practitioners should obtain appropriate consent as
required. A compendium of state HIV-testing laws can
be found at www.ucsf.edu/hivcntr.
In states where laws and regulations require written
informed maternal consent for testing, practitioners
should work to modify the laws or regulations to permit
opt-out consent. Such an advocacy effort is best under-
taken with a broad coalition of interested parties
throughout the state, including state and local health
departments, the state AAP chapter, representatives of
the ACOG and the American Academy of Family Physi-
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cians, nursing groups, community groups interested in
maternal health, and AIDS activist organizations.
Mandatory HIV testing of the newborn infant whose
mother has not been tested during pregnancy or in the
immediate postpartum period has been associated with
high rates of prenatal testing in New York state7 and may
act as a safety net for identifying infants who would not
have been tested otherwise. There has not been a study
to compare the percentage of women tested before de-
livery in programs with mandatory newborn testing
compared with those with opt-out consent policies.
Therefore, an evidence-based recommendation for or
against mandatory newborn testing cannot be made. A
few states have passed laws that require HIV testing of
newborn infants without maternal consent when the
HIV-infection status of the mother is unknown. In states
where legislation aimed at mandating testing of new-
born infants has been proposed, issues have been raised
regarding the ethics and legality of this approach, be-
cause it diagnoses HIV infection in the mother without
her consent for testing. In addition, concerns have been
raised about the costs of such screening programs, given
the already high numbers of mothers and newborn in-
fants tested in voluntary (opt-out) programs. Regardless
of the form of consent used in testing programs, it is
important that the results of infant testing be returned as
rapidly as possible so that ARV prophylaxis for the infant
can be started promptly if needed. Infant ARV prophy-
laxis is likely to be less effective in the prevention of
MTCT of HIV when started later than 12 hours after
birth. Optimal prevention of MTCT of HIV requires iden-
tification of the mother’s HIV status during pregnancy.
TIMING OF TESTING IN PREGNANCY
As noted, testing of the pregnant woman early in preg-
nancy is recommended to allow informed and timely
therapeutic decisions concerning health care for her and
for prevention of MTCT of HIV.11 A second HIV test
during the third trimester has been shown to be cost-
effective under certain conditions,40 and the CDC recom-
mends that a second test be performed late in pregnancy
but at36 weeks’ gestation for women who are in areas
of high incidence, for women delivering in hospitals
with HIV prevalence in pregnant women of at least 1 in
1000, and for women at high risk of acquiring HIV
(women with a sexually transmitted infection diagnosed
during pregnancy, injection drug users and their part-
ners, women who exchange sex or money for drugs,
women who are sex partners of HIV-infected persons,
women who have had a new or more than 1 sex partner
during pregnancy, or women with signs/symptoms of
acute HIV infection).11 However, because risk-based and
prevalence-based testing programs may be difficult to
implement, some practitioners and hospitals choose to
test all pregnant women a second time late in pregnancy,
even in the absence of specific prevalence or risk data.
Because of the high levels of viral replication observed
with acute HIV infection, women who become infected
with HIV during pregnancy have a particularly high risk
of transmitting HIV to their infants. For women whose
HIV status is unknown at the time of presentation in
labor, testing should be timed so that results are avail-
able to allow predelivery administration of prophylaxis if
indicated. For a newborn infant whose mother’s HIV
status is unknown, testing should be performed quickly
enough so that results can be available for infant ARV
prophylaxis to begin within 12 hours of birth, as stated
previously.11
CONCLUSIONS
Universal HIV testing of pregnant women is standard
care in the United States. Identification of HIV infection
early in pregnancy allows the greatest ability to treat the
pregnant woman for her HIV infection for her own
health and to prevent MTCT of HIV. Rapid HIV antibody
testing allows for timely identification of HIV infection in
women even late in pregnancy, during labor, or in the
immediate postpartum period as well as HIV exposure in
their newborn infants. The results can be available
quickly enough to implement successful ARV interven-
tions that can reduce MTCT of HIV when administered
to the mother started later in pregnancy or in labor or to
the infant when administered within the first few hours
of life.
RECOMMENDATIONS
1. Information about HIV infection, prevention of
MTCT of HIV, and HIV antibody testing should be
provided routinely as part of a comprehensive pro-
gram of health care for pregnant women.
2. Documented, routine HIV antibody testing should
be performed for all pregnant women in the United
States after notifying the patient that testing will be
performed, unless the patient declines HIV testing
(opt-out consent or right of refusal). All HIV anti-
body testing should be performed in a manner con-
sistent with state and local laws.
3. In states where laws and regulations require written
informed maternal consent for testing, health care
professionals should work to modify the laws or
regulations to permit opt-out consent.
4. All programs for the detection of HIV infection in
pregnant women and their infants should periodi-
cally evaluate the proportion of women who are not
tested. Programs in which an unacceptably high pro-
portion of women do not receive HIV antibody test-
ing should examine the reasons and make appropri-
ate program modifications as needed.
5. Repeat HIV antibody testing is recommended in the
third trimester, preferably before 36 weeks’ gesta-
tion, for women in states with high HIV prevalence
in women 15 to 45 years of age, for women deliv-
ering in hospitals with HIV prevalence of 1 or more
in 1000 pregnant women screened, or for women at
increased risk of acquiring HIV (women with a sex-
ually transmitted infection diagnosed during preg-
nancy, injection drug users and their partners,
women who exchange sex or money for drugs,
women who are sex partners of HIV-infected per-
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sons, women who have had a new or more than 1
sex partner during pregnancy, or women with
signs/symptoms of acute HIV infection). Because
prevalence-based testing may be difficult to imple-
ment and individual risk assessment is unreliable
and the risk of MTCT of HIV is high in women who
first acquire HIV infection during pregnancy, some
experts recommend that repeat HIV screening be
considered for all pregnant women in the third
trimester.
6. For women in labor with undocumented HIV-infec-
tion status during the current pregnancy, maternal
HIV antibody testing with opt-out consent, using a
rapid HIV antibody test, is recommended. For
women with a positive HIV rapid antibody test re-
sult, ARV prophylaxis should be administered to the
mother and newborn infant on the basis of the
positive rapid antibody test result without waiting
for results of confirmatory HIV testing, and breast-
feeding should not occur. Assistance with the imme-
diate initiation of hand and pump expression to
stimulate milk production should be offered to the
mother, given the possibility that the confirmatory
test results may be negative. If confirmatory test
results are negative, prophylaxis should be stopped
and breastfeeding may be initiated.
7. Rapid HIV antibody testing should be available on a
24-hour basis at all facilities with an obstetric unit
and/or newborn nursery of any level.
8. The health care professional for the newborn infant
needs to be informed promptly of maternal HIV
serostatus so that appropriate care and testing of the
newborn infant can be accomplished and so that
ARV prophylaxis can be administered to HIV-ex-
posed infants. The infant medical chart needs to
contain documentation of the maternal HIV-infec-
tion status. Presence of maternal HIV-infection sta-
tus on the maternal and infant record should be a
standard measure of the adequacy of hospital care
for the mother and infant.
9. For newborn infants whose mother’s HIV serostatus
is unknown, the newborn infant’s health care pro-
fessional should order rapid HIV antibody testing to
be performed for the mother or the newborn, with
appropriate consent as required by state or local law.
Results should be reported to health care profession-
als quickly enough to allow effective ARV prophy-
laxis to be administered, if indicated, to the infant as
soon as possible after birth but certainly by 12 hours
after birth. ARV prophylaxis for the newborn infant
should be administered promptly on the basis of a
positive rapid antibody test result without waiting
for results of confirmatory HIV testing. Breastfeed-
ing should be avoided. Confirmatory testing should
be performed, and assistance with hand and pump
expression to stimulate milk production should be
offered to the mother, given the possibility that the
confirmatory test results may be negative. If confir-
matory test results are negative (indicating that the
infant was not truly exposed to HIV), then ARV
prophylaxis should be stopped and breastfeeding
may be initiated. If the confirmatory test result is
positive, infants should receive ARV prophylaxis for
6 weeks after birth, and they should not breastfeed.
Prophylaxis is most effective if administered within
12 hours of birth but may still be effective when
administered as late as at 48 hours of life.
10. The full 6-week course of infant ARV prophylaxis,
and careful instructions for its administration,
should be provided to the family before discharge
from the hospital. Payment for this should be cov-
ered by all third-party payers.
11. If the mother or infant has a positive test result for
HIV antibody, the infant should not breastfeed.
12. In the absence of parental availability for consent to
test the newborn infant for HIV antibody, the new-
born infant should be tested, ideally within the first
12 hours of life. State and local jurisdictions need to
develop procedures to facilitate the rapid evaluation
and testing of the infant.
13. For infants of unknown HIV exposure status at the
first health supervision visit, HIV antibody testing
with appropriate consent should be performed to
guide appropriate care and follow-up testing if
needed.
14. Care of the mother, fetus, newborn, and child with
perinatal exposure to HIV should be performed in
consultation with specialists in obstetric and pediat-
ric HIV infection.
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